Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US6699476B1 · kind B1 · utility
Inventors
Key dates
| Filing date | Jul 12, 2000 |
| Grant date | Mar 2, 2004 |
| Priority date | — |
| Expiry date | Jul 12, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.